Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

155
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
155
Pneumonia IV: Management01:28

Pneumonia IV: Management

267
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
267
Antibiotic Selection00:57

Antibiotic Selection

51.9K
Overview
51.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing clinical utility of AI-based antimicrobial resistance models: a perspective.

mBio·2026
Same author

Standardized numbering and alignment of the KPC family of β-lactamases.

Antimicrobial agents and chemotherapy·2026
Same author

Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> study.

Antimicrobial agents and chemotherapy·2026
Same author

Sulbactam-durlobactam and cefiderocol combination treatment of <i>Burkholderia cenocepacia</i>-associated Fitz-Hugh-Curtis syndrome.

Antimicrobial agents and chemotherapy·2026
Same author

Role of Ambler Position 104 in Defining Substrate Specificity in the KPC Family of β-Lactamases.

ACS infectious diseases·2026
Same author

A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.

mBio·2026

Related Experiment Video

Updated: May 13, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.4K

Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens.

Richard R Watkins1, Tracy L Lemonovich2,3, Alejandro J Vila4,5

  • 1Division of Infectious Diseases, Northeast Ohio Medical University, Rootstown, Ohio, USA.

The Journal of Infectious Diseases
|May 12, 2025
PubMed
Summary

New antibiotic cefepime-taniborbactam shows promise against difficult gram-negative infections. This novel combination targets key resistance enzymes, offering a potential new weapon against antimicrobial resistance.

Keywords:
antibioticsantimicrobial resistancecefepime-taniborbactamcephalosporinsgram-negative pathogens

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

25.9K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.4K

Related Experiment Videos

Last Updated: May 13, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.4K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

25.9K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.4K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Medicinal Chemistry

Background:

  • Antimicrobial resistance (AMR) is a growing global health threat, necessitating novel therapeutic agents.
  • Multidrug-resistant (MDR) gram-negative pathogens pose a significant challenge due to limited treatment options.

Purpose of the Study:

  • To review the development and potential clinical applications of cefepime-taniborbactam.
  • To discuss the medicinal chemistry, pharmacokinetics, pharmacodynamics, and spectrum of activity of this novel antibiotic combination.

Main Methods:

  • Review of scientific literature on taniborbactam and cefepime-taniborbactam.
  • Analysis of preclinical and clinical data regarding efficacy against MDR gram-negative bacteria.
  • Discussion of β-lactamase inhibition mechanisms and resistance pathways.

Main Results:

  • Taniborbactam is a potent inhibitor of Ambler class A, B, C, and D β-lactamases, including metallo-β-lactamases.
  • Cefepime-taniborbactam demonstrates broad-spectrum activity against challenging gram-negative pathogens, including carbapenem-resistant Enterobacterales and MDR Pseudomonas aeruginosa.
  • The combination exhibits favorable pharmacokinetic and pharmacodynamic properties.

Conclusions:

  • Cefepime-taniborbactam represents a significant advancement in the fight against MDR gram-negative infections.
  • Further clinical investigation is warranted to define its precise role in treating serious bacterial infections.
  • This novel inhibitor combination offers a promising therapeutic option for overcoming antimicrobial resistance.